Partners Sas Sofinnova Net Worth

The estimated Net Worth of Partners Sas Sofinnova is at least $19.5 Million dollars as of 29 October 2014. Partners Sofinnova owns over 10,000 units of Flexion Therapeutics Inc stock worth over $19,257,562 and over the last 11 years Partners sold FLXN stock worth over $200,000.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Partners Sofinnova FLXN stock SEC Form 4 insiders trading

Partners has made over 2 trades of the Flexion Therapeutics Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently Partners sold 10,000 units of FLXN stock worth $200,000 on 29 October 2014.

The largest trade Partners's ever made was buying 230,769 units of Flexion Therapeutics Inc stock on 18 February 2014 worth over $2,999,997. On average, Partners trades about 120,385 units every 126 days since 2014. As of 29 October 2014 Partners still owns at least 2,095,491 units of Flexion Therapeutics Inc stock.

You can see the complete history of Partners Sofinnova stock trades at the bottom of the page.

What's Partners Sofinnova's mailing address?

Partners's mailing address filed with the SEC is 16-18 RUE DE 4 SEPTEMBRE, , PARIS, I0, 75002.

Insiders trading at Flexion Therapeutics Inc

Over the last 11 years, insiders at Flexion Therapeutics Inc have traded over $7,066,621 worth of Flexion Therapeutics Inc stock and bought 7,091,809 units worth $98,920,816 . The most active insiders traders include Holdings A/S Novo, Bradley J Ph D Bolzon und Samuel D Colella. On average, Flexion Therapeutics Inc executives and independent directors trade stock every 24 days with the average trade being worth of $609,564. The most recent stock trade was executed by Christina Willwerth on 19 July 2021, trading 3,945 units of FLXN stock currently worth $25,445.

What does Flexion Therapeutics Inc do?

Flexion Therapeutics is a biopharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of people with musculoskeletal conditions, beginning with osteoarthritis, the most common form of arthritis. The Company's core values are focus, ingenuity, tenacity, transparency and fun.

Complete history of Partners Sofinnova stock trades at Flexion Therapeutics Inc

Flexion Therapeutics Inc executives and stock owners

Flexion Therapeutics Inc executives and other stock owners filed with the SEC include:

• Michael Clayman,
  President, Chief Executive Officer, Director
• David Arkowitz,
  Chief Financial Officer
• Scott Kelley,
  Chief Medical Officer
• Mark Levine,
  General Counsel and Corporate Secretary
• Dr. Neil Bodick,
  Consultant
• Patrick Mahaffy,
  Independent Chairman of the Board
• Sandesh Mahatme,
  Independent Director
• Samuel Colella,
  Independent Director
• Alan Milinazzo,
  Independent Director
• Mark Stejbach,
  Independent Director
• C. Ann Merrifield,
  Independent Director
• Scott Canute,
  Independent Director
• Heath Lukatch,
  Independent Director
• Scott Young,
  IR Contact Officer
• Elizabeth Kwo,
  Director
• Christina Willwerth,
  Chief Strategy Officer
• Kerry Wentworth,
  Chief Regulatory Officer
• Melissa Layman,
  Chief Commercial Officer
• John Magee,
  VP of Sales
• Carolyn Beaty Scimemi,
  VP, Legal Affairs & Chief Compliance Officer
• David A. Arkowitz M.B.A.,
  Chief Financial Officer
• Ventures Iii, Llc Versant V...,
  
• Yamo Deniz,
  Chief Medical Officer
• Frederick W Driscoll,
  Chief Financial Officer
• Barbara N Bolzon Bradley J ...,
  
• William T. Andrews,
  Chief Medical Officer
• Utpal Koppikar,
  Director
• Neil Bodick,
  Chief Scientific Officer
• Ventures Ii Lp5 Am Co Inves...,
  
• Holdings A/S Novo,
  10% owner
• Partners Sas Sofinnova,
  10% owner
• Venture Capital Iii, L.P.Bo...,
  
• Venture Capital Iii, L.P.Ve...,
  
• Rafael Tordjman,
  Director
• Andrew J. Schwab,
  Director
• Bradley J Ph D Bolzon,
  Director
• Venture Capital Iii, L.P.Ve...,
  
• Inc Pfizer,
  10% owner
• Management, Llc Newtyn,
  10% owner
• Adam Muzikant,
  Chief Business Officer